MDGL Overview
Upcoming Projects (MDGL)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (MDGL)
-
A Second Opinion: An updated look at the potential of Survodutide for MASH treatment
Tickers: BOEHRINGER INGELHEIM, ZEAL, MDGL
Executed On: Dec 13, 2024 at 04:30 PM EST -
An updated look at the potential of Survodutide for MASH treatment
Tickers: BOEHRINGER INGELHEIM, ZEAL, MDGL
Executed On: Dec 12, 2024 at 06:00 PM EST -
Prescriber check in on the use of Rezdiffra to treat Metabolic dysfunction-associated steatohepatitis (MASH)
Ticker: MDGL
Executed On: Dec 05, 2024 at 04:30 PM EST -
A Third Opinion: Looking at the use of Rezdiffra for MASH and reviewing the recent data on Tirzepatide from Eli Lilly
Tickers: MDGL, LLY
Executed On: Aug 07, 2024 at 10:00 AM EDT -
A Second Opinion: Looking at the use of Rezdiffra for MASH and reviewing the recent data on Tirzepatide from Eli Lilly
Tickers: MDGL, LLY
Executed On: Aug 07, 2024 at 08:00 AM EDT -
Looking at the use of Rezdiffra for MASH and reviewing the recent data on Tirzepatide from Eli Lilly
Tickers: LLY, MDGL
Executed On: Aug 01, 2024 at 11:00 AM EDT -
A Third Look: Discussing the potential of Madrigal Pharmaceuticals Rezdiffra™ (resmetirom) and the new data from the Phase 3 MAESTRO-NASH Study presented at the EASL Congress
Ticker: MDGL
Executed On: Jun 27, 2024 at 05:00 PM EDT -
A Second Look: Discussing the potential of Madrigal Pharmaceuticals Rezdiffra™ (resmetirom) and the new data from the Phase 3 MAESTRO-NASH Study presented at the EASL Congress
Ticker: MDGL
Executed On: Jun 18, 2024 at 04:30 PM EDT -
Discussing the potential of Madrigal Pharmaceuticals Rezdiffra™ (resmetirom) and the new data from the Phase 3 MAESTRO-NASH Study presented at the EASL Congress.
Ticker: MDGL
Executed On: Jun 18, 2024 at 04:00 PM EDT -
A Second Look: Discussing the recent FDA approval of Madrigal Pharma's Rezdiffra, a liver-directed oral therapy that is designed to target key underlying causes of NASH/MASH
Ticker: MDGL
Executed On: Apr 03, 2024 at 03:15 PM EDT -
Discussing the recent FDA approval of Madrigal Pharma's Rezdiffra, a liver-directed oral therapy that is designed to target key underlying causes of NASH/MASH
Ticker: MDGL
Executed On: Apr 03, 2024 at 08:00 AM EDT -
A Fourth Look: Exploring the Potential of Madrigal Pharmaceuticals' Resmetirom in Treating NASH: Insights from the Phase 3 MAESTRO-NASH Trial
Ticker: MDGL
Executed On: Mar 06, 2024 at 12:30 PM EST -
A Third Look: Exploring the Potential of Madrigal Pharmaceuticals' Resmetirom in Treating NASH: Insights from the Phase 3 MAESTRO-NASH Trial
Ticker: MDGL
Executed On: Mar 04, 2024 at 04:00 PM EST -
Discussing Akero's recent announcement of their Phase 2b SYMMETRY study results evaluating efruxifermin (EFX) in patients with compensated cirrhosis due to NASH
Tickers: AKRO, MDGL, ENTB, VKTX
Executed On: Jan 10, 2024 at 05:15 PM EST -
A Second Look: Exploring the Potential of Madrigal Pharmaceuticals' Resmetirom in Treating NASH: Insights from the Phase 3 MAESTRO-NASH Trial
Ticker: MDGL
Executed On: Dec 06, 2023 at 01:00 PM EST -
Exploring the Potential of Madrigal Pharmaceuticals' Resmetirom in Treating NASH: Insights from the Phase 3 MAESTRO-NASH Trial
Ticker: MDGL
Executed On: Dec 05, 2023 at 12:00 PM EST -
A Second Look: Examining the recent data from the MAESTRO-NASH phase 3 trial of Madrigal Pharmaceuticals resmetirom in NASH
Ticker: MDGL
Executed On: Feb 06, 2023 at 03:00 PM EST -
Examining the recent data from the MAESTRO-NASH phase 3 trial of Madrigal Pharmaceuticals resmetirom in NASH
Ticker: MDGL
Executed On: Jan 05, 2023 at 10:00 AM EST -
A Second Look at resmetirom as a therapy for nonalcoholic steatohepatitis
Ticker: MDGL
Executed On: Oct 21, 2022 at 03:00 PM EDT -
A First Look at resmetirom as a therapy for nonalcoholic steatohepatitis
Ticker: MDGL
Executed On: Oct 14, 2022 at 07:00 AM EDT
Upcoming & Overdue Catalysts (MDGL)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (MDGL)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
